9M 2023 Financial Overview
9M 2023: APPENDIX
Lu AF82422 - Potential first disease
modifying therapy in MSA
Lu AF82422 (a-synuclein) in phase II
Neuron
26
Clinical
Trials
Alpha-synuclein
♥Lu AF82422
Microglia
Oligodendroglial Cell
Phase 2
AMULET study
Analysis + ph3
go/no-go decision
TALISMAN EU data to enrich
AMULET placebo arm
Natural
history
study
TALISMAN study
Phase 3
UMSARS: unified multiple system atrophy rating scale. MSA: multiple system atrophy
Efficacy analysis
Medical condition
•
Alpha-synucleinopathies: Multiple System
Atrophy - a rare, aggressive, disease with a
high unmet medical need
Molecule
• Anti alpha-synuclein IgG1 antibody
•
Binds to multiple species, including C-terminal
truncated forms; target engagement on
monomers in CSF shown
Clinical development phase
.
Phase II: Innovative and adaptive, supported
by biomarkers
UMSARS Part I and Part II Total Score; 48-
72 weeks of treatment
60 patients randomized 2:1 (active:
placebo)View entire presentation